Overview
Retatrutide, also known by the research name LY3437943, is an investigational peptide that acts as a triple agonist of the GLP-1, GIP, and glucagon receptors. It was developed as part of the new generation of incretin and metabolic drugs, whose aim is to affect appetite, insulin secretion, body weight, and energy expenditure in parallel [1,2]. The distinctive feature of Retatrutide is that it is not a GLP-1 agonist alone, and not merely a dual agonist like drugs acting on GLP-1 and GIP. It also adds activity at the glucagon receptor, which produces a more complex biological profile. Glucagon is known mainly as a hormone that raises blood glucose, but activation of its receptor may also be associated with increased energy expenditure and with changes in lipid metabolism [1,2]. As of June 2026, Retatrutide is in advanced clinical development, with Phase 2 studies published in 2023 and a Phase 3 study in type 2 diabetes published in 2026 [1-3]. This means that there is more substantial clinical literature than for many other research peptides, but a distinction is still required between trial results and approval and broad clinical use.
Biological Mechanism
GLP-1 is an incretin hormone secreted after a meal and involved in enhancing glucose-dependent insulin secretion, suppressing postprandial glucagon, slowing gastric emptying, and increasing satiety. GIP is another incretin that affects insulin secretion and beta-cell function, and it also has effects in adipose tissue and in the broader metabolic system [1,2]. The glucagon receptor adds a further layer. On one hand, glucagon increases glucose production in the liver. On the other hand, controlled activation of the glucagon pathway may increase energy expenditure, affect liver fat, and contribute to weight loss when it is combined with GLP-1 and GIP activity [1,2]. The triple combination is intended to create a balance between reduced appetite, improved glycemic control, and an effect on metabolism. However, such a mechanism is not simpler than the GLP-1 mechanism, but rather more complex. Therefore, long-term studies are required to assess not only weight loss and HbA1c, but also cardiac, hepatic, pancreatic, and metabolic safety.
Research Evidence
In a Phase 2 study published in the New England Journal of Medicine in 2023, Retatrutide was examined in adults with obesity. After 48 weeks, significant weight loss was reported, with a dose-dependent effect of high magnitude relative to previous generations of incretin drugs [1]. The study established Retatrutide as one of the leading candidates in the field of metabolic treatment, but the follow-up duration and sample size were still an intermediate stage in development. In another Phase 2 study published in the Lancet in 2023, Retatrutide was examined in patients with type 2 diabetes. The study showed improvement in HbA1c and weight loss, alongside side effects mainly of the gastrointestinal system, similar to the pattern known in the family of incretin agonists [2]. In 2026, a Phase 3 study of the TRANSCEND-T2D-1 type was published in the Lancet, examining Retatrutide in patients with type 2 diabetes. The study presented significant improvement in glycemic control and body weight, and added an important clinical layer beyond the Phase 2 studies [3]. At the same time, questions about persistence over years, cardiovascular outcomes, rare effects, and the effect after treatment discontinuation require further follow-up.
Advanced Clinical Development and the Current Evidence Picture
Beyond the Phase 2 studies, Retatrutide advanced to a broad Phase 3 program. TRIUMPH-1 was registered as a Phase 3 study in participants with obesity or overweight, including subpopulations with obesity-related complications [5]. Company data published in 2026 described significant weight loss in this study, but it is important to distinguish between a company's initial announcement and a full peer-reviewed article [6]. TRIUMPH-4 examined a specific population of participants with obesity or overweight together with osteoarthritis of the knee [7]. The preliminary data emphasized not only weight loss, but also improvement in pain and function according to WOMAC measures. Cautious interpretation should take into account that part of the improvement in pain may result from a reduction in the mechanical load on the knee, and not necessarily from direct anti-inflammatory activity of the molecule. This distinction is important because it separates a systemic metabolic effect from a direct effect on joint tissue. Another area is MASLD, a fatty liver disease associated with metabolic disorder. In a Phase 2a study published in Nature Medicine, it was found that Retatrutide reduced liver fat on a research measurement, and the reduction was associated with changes in weight, abdominal fat, and metabolic measures [4]. This finding fits the biological rationale of triple agonism, because the liver is a central organ in the glucagon, lipid, and insulin-sensitivity pathways. A significant difference between Retatrutide and many other research peptides is the depth of the clinical program. There are randomized controlled trials in humans, including Phase 2 and Phase 3 [1-3,5]. At the same time, even in an advanced clinical program there are questions that require time: the effect after treatment discontinuation, preservation of lean body mass, cardiovascular outcomes, liver and pancreas function, uncommon neurological effects, as well as patterns of persistence and tolerability in a broad population. Therefore, the value of Retatrutide today lies in the combination of strong clinical results and the need to complete regulatory follow-up and full publication of all outcomes.
Safety & Limitations
The common side effects in studies on Retatrutide were mainly in the gastrointestinal system, including nausea, diarrhea, vomiting, and constipation [1,2]. In some studies, changes in heart rate or additional metabolic measures were also reported, and therefore the safety assessment is not limited only to gastrointestinal tolerability. Activity at the glucagon receptor requires special attention. Although the combination with GLP-1 and GIP may balance some of the effects on glucose, glucagon is a central metabolic pathway in the liver. Therefore it is important to assess over time the effects on glucose, liver, lipids, appetite, lean body mass, and cardiovascular systems. At this stage, Retatrutide presents impressive clinical data, but it still requires regulatory evaluation and long-term follow-up. Large studies can identify rare or late effects that do not necessarily appear in Phase 2 studies or in early Phase 3 studies.
Interpretation Limits Between Research and Drug Development
Retatrutide is in a different situation from most of the research peptides on the list, because it has a broad clinical program and randomized trials in humans [1-5]. However, here too a distinction must be made between efficacy on intermediate measures and a full understanding of long-term benefit. Weight loss, reduction in HbA1c, and reduction in liver fat are significant results, but regulators and health systems also examine cardiac safety, effects on the gallbladder, pancreas, heart rate, kidney function, lean body mass, and rare events. The addition of glucagon receptor agonism is a possible biological advantage, but also a source of questions. Glucagon is involved in glucose production in the liver, in the use of lipids, and in energy expenditure. When it is combined with GLP-1 and GIP, stronger weight loss may be obtained, but it must be ensured that metabolic balance is maintained over time [1,4]. Another question is what happens after significant weight loss. Future studies need to assess weight maintenance, appetite, nutrition, muscle mass, bone density, and quality of life. Therefore, Retatrutide is an example of a peptide where the problem is not a complete absence of evidence, but rather the need to follow a potent molecule for enough time to understand the full benefit-risk profile.
Summary
Retatrutide is a triple agonist of the GLP-1, GIP and glucagon receptors, and it represents an advanced direction in the research of obesity and type 2 diabetes [1-3]. The clinical data published to date are presented as research background only; Retatrutide is an experimental substance that is not approved for marketing. Its complex biological profile requires broad and prolonged monitoring, and its central value today lies in demonstrating a research direction of a multi-pathway metabolic effect, alongside a continued need for safety and regulatory assessment.
Selected Research Sources
- Jastreboff A.M. et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 2023. PMID: 37366315
- Rosenstock J. et al. Retatrutide for type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet, 2023. PMID: 37385280
- Bajaj H.S. et al. Efficacy and safety of retatrutide in people with type 2 diabetes, TRANSCEND-T2D-1. Lancet, 2026. PMID: 42250575
- Sanyal A.J. et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 2024. NIH.gov
- ClinicalTrials.gov. TRIUMPH-1, A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight. NCT05929066. clinicaltrials.gov
- Eli Lilly and Company. Retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial, TRIUMPH-1. May 21, 2026. gcs-web.com
- Eli Lilly and Company. Retatrutide delivered weight loss and relief from osteoarthritis pain in Phase 3 TRIUMPH-4. December 11, 2025. lilly.com
- Eli Lilly and Company. Retatrutide drove improvements in weight, A1C, knee osteoarthritis pain and obstructive sleep apnea. June 6, 2026. lilly.com
